Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
作者
Saura C,J. Cortés,S. Modi,S. B. Kim,E. Hamilton,Hurvitz Sa,I. E. Krop,G. Curigliano,H. Iwata,S. A. Im,P. Herbolsheimer,M. Karnoub,A. Boran,Kuwahara Y,A. Egorov,F. Andre